The Tokyo-based $4.5billion-company, Eisai Co, Ltd has established its pharmaceuticals marketing subsidiary, Eisai Pharmaceuticals India Private Ltd. at Mumbai, India on October 27, 2004.

In India, Eisai Pharmaceuticals India Private Ltd, with a capital of Rs 100 million, will sell and promote pharmaceuticals developed by Eisai including Aricept, an Alzheimer's disease treatment, and Aciphex/Pariet, a proton pump inhibitor, and other pharmaceuticals.

The newly established subsidiary company will establish a production-cost structure that enables the company to operate in the pharmaceutical market in India, and will provide a stable supply of quality products and appropriate product information for safe and proper usage to meet the medical needs of Indian patients, the statement from company said.

It will have the operations of application for pharmaceuticals registration, clinical research, commission of manufacture, promotion/sale of pharmaceuticals and import of drug materials.

Eisai has around 7,700 employees world wide and 3 production facilities- Misato Plant (Saitama Prefecture), Kawashima Plant (Gifu Prefecture), Kashima Plant (Ibaraki Prefectire) in Japan along with R&D facilities -Tsukuba Research Laboratories, Eisai Research Institute of Boston, Eisai London Research Laboratories. It has overseas subsidiaries in USA, UK, Germany, France, Indonesia, Singapore, Malaysia,Thailand, Philippines, Hong Kong, Taiwan, China, etc.

In the year ended on March 31, 2004, Eisai made a consolidated sale of 500,164 million Yen.